Korro Bio Inc and Frequency Therapeutics Inc (NASDAQ: FREQ) announced an all-stock merger transaction. Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. Frequency Therapeutics has discontinued developing its remyelination program for Multiple Sclerosis as it explores strategic alternatives for the program. Suppose Frequency Therapeutics has not otherwise monetized its remyelination program before the closing of the proposed
A new UCLA Health-led study has found that the pregnancy hormone estriol can reverse the degeneration of myelin in the cerebral cortex area of the brain
Patients with rheumatoid arthritis who take a tumor necrosis factor inhibitor do not appear to have a consistent and significant risk for developing a demyelinating disease.
Blood-brain barrier breakdown in multiple sclerosis leads to immune cell infiltration into the central nervous system. Antigen presentation at the barrier promotes CD8+ T cell entry, triggering focal breakdown and hindering their invasion.